Switzerland’s Actelion says that earnings almost doubled in 2006 thanks to strong sales of its pulmonary artery hypertension product Tracleer.

Net income was up 92% to 241 million Swiss francs ($195 million), while revenues climbed 43% to 945.7 million francs, the vast majority of which came from Tracleer (bosentan). Sales of the latter rose 42% to 898.7 million francs. Also contributing to Actelion’s coffers was Zavesca (miglustat), its new treatment for Gaucher disease, which brought in 25.4 million francs, a rise of 76.4%.

The company’s chief executive, Jean-Paul Clozel, said that by the end of 2007, Actelion expects to have ten different chemical entities in clinical development, “five alone in Phase III.” He added that all of these programmes “focus on areas of high unmet medical need."

Actelion added that it expects net revenues of between 1.18-1.23 billion francs in 2007, but operating income would be hit by higher non-cash charges, mainly related to its $420 million acquisition of CoTherix.